Recombinant IL-1Ra (generic anakinra) is fully active in blocking the IL-1 receptor 1 (IL-1R1), and thus the activities of IL-1α and IL-1β, and is approved for the treatment of rheumatoid arthritis and several other diseases [62]. This evidence concerns the gene IL1B and rheumatoid arthritis.